A single dose of Johnson & Johnson’s JNJ.N experimental COVID-19 vaccine produced a strong immune response against the novel coronavirus in an early-to-mid stage clinical trial, according to interim results published on Friday.
The vaccine, called Ad26.COV2.S, was equally well-tolerated at two different doses, the results showed. A single shot, versus a rival two-dose approach being tested by Moderna Inc MRNA.O and Pfizer Inc PFE.N, could simplify distribution of the vaccine.
The results, released on the medical website medRxiv, have not been peer-reviewed. (bit.ly/2G3Ni1X)
Researchers, including those from J&J’s unit Janssen Pharmaceuticals, said 98% of participants with data available for the interim analysis had neutralizing antibodies, which defend cells from pathogens, 29 days after vaccination.
“Overall, the vaccine is doing what you would expect it to do if you were to move it to Phase 3 trials,” Bloom said.
https://www.reuters.com/article/health-coronavirus-johnson-johnson-vacci-idUSKCN26G2YCHELP US SPREAD GOOD NEWS!
I run this site in my spare time and thoroughly enjoy giving you all positive news! If you’ve enjoyed the site we’d love for you to help me share the good news far and wide, share us on Reddit, your Facebook or your Twitter and spread a little positivity around.
ENJOY FEEL GOOD, INSPIRING STORIES AND VIDEOS ?
Our new page here is just what you need, with just good news, feel good stories unrelated to COVID.
